$CTXR News
Last published 1d ago
- 1d agoCTXRCTORCitius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in LondonPR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
- 2w agoCTXRCitius Pharmaceuticals, Inc. - PRESS RELEASE, DATED OCTOBER 26, 2026Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoCTORCTXRCitius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026PR NewswireCRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of
- 1mo agoCTXRCTORCitius Pharmaceuticals to Participate in October 2026 Investor ConferencesPR NewswireChairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity ConferenceCRANFORD, N.J., Oct. 12, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
- 2mo agoCTXRDISRUPTIVE GROWTH CONFERENCE - CITIUS PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Well, thank you, everyone that's in here right now. Our next presenter is Leonard Major with Sidious Pharmaceuticals. Take it away. Thank you for the introduction. I appreciate all of you taking the time to be
- 2mo agoCTXRCTORCitius Pharmaceuticals to Participate in September 2026 Investor ConferencesPR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
- 3mo agoCTXRCTORCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdatePR Newswire$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®$17 million in cash and cash equivalents as of June 30, 2026Expanded LYMPHIR commercial and medical affairs
- 3mo agoCTORCTXRCitius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdatePR Newswire$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR® launch progressesStrong institutional demand drives growth in total vials ordered and number of institutions orderingLYMPHIR ordered by 44
- 3mo agoCTORCTXRCitius Oncology Expands Board with Appointment of Independent Director Jonathan PeriPR NewswireCRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc.
- 5mo agoCTORCTXRCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic MalignanciesPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
- 6mo agoCTORCTXRCitius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business UpdatePR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius...
- 6mo agoCTXRCTORCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business UpdatePR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
- 6mo agoCTORCTXRCitius Oncology Ships First International Order of LYMPHIR™ to EuropePR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
- 6mo agoCTXRCitius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq RulesPR NewswireCitius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
- 6mo agoCTXRCitius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq RulesPR NewswireCitius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
- 7mo agoCTORCTXRCitius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical DevelopmentPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
- 7mo agoCTORCTXRCitius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma ExpertsPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
- 8mo agoCTORCTXRCitius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic CancersPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
- 8mo agoCTORCTXRCitius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell LymphomaPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
- 8mo agoCTXRCitius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development ProgramPR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
- 9mo agoCTORCTXRCitius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™PR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
- 9mo agoCTXRCTORCitius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™PR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
- 10mo agoCTXRCTORCitius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdatePR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
- 10mo agoCTORCTXRCitius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdatePR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
- 11mo agoCTORCTXRCitius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesPR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius...
- 11mo agoCTORCTXRCitius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesPR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius...
- 11mo agoCTORCTXRCitius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-KimPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
- 11mo agoCTORCTXRCitius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)PR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
- 11mo agoCTORCTXRCitius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual MeetingPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
- 11mo agoCTORCTXRCitius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI IntegrationPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
- 1y agoCTXRCitius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq RulesPR NewswireCitius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
- 1y agoCTXRCitius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq RulesPR NewswireCitius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
- 1y agoCTXRCTORCitius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 ConferencesPR NewswireCitius Pharmaceuticals, Inc. (Nasdaq: CTXR) and Citius Oncology, Inc. (Nasdaq: CTOR) today announced that management will be participating in three...
- 1y agoCTORCTXRCitius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™PR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
- 1y agoCTORCTXRCitius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
- 1y agoCTORCTXRCitius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR LaunchPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
- 1y agoCTXRCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business UpdatePR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
- 1y agoCTORCTXRCitius Oncology Announces Closing of $9.0 Million Public OfferingPR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq:...
- 1y agoCTORCTXRCitius Oncology Announces Pricing of $9.0 Million Public OfferingPR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq:...
- 1y agoCTORCTXRCitius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with CencoraPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced ...
- 1y agoCTXRCitius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementPR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification from The...
- 1y agoCTORCTXRCitius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025PR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
- 1y agoONCYTPSTCTORCTXR+1After Major Oncology Conference, All Eyes Turn to Industry InnovationPR NewswireAfter the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and...
- 1y agoCTXRCitius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq RulesPR NewswireCitius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
- 1y agoCTXRCitius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq RulesPR NewswireCitius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
- 1y agoCTORCTXRCAHCitius Oncology Enters into Distribution Services Agreement with Cardinal HealthPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
- 1y agoCTXRCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business UpdatePR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
- 1y agoCTXRCTORCitius Pharmaceuticals to Present at the Jefferies Global Healthcare ConferencePR NewswireCitius Pharmaceuticals, Inc. (Nasdaq: CTXR) and its oncology subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), today announced that Leonard Mazur,...
- 1y agoCTXRCitius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common StockPR NewswireCitius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
- 1y agoCTXRCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business UpdatePR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...